Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

Bio-Rad Laboratories, Inc. (BIO) posted second-quarter 2024 adjusted earnings per share (EPS) of $3.11, which beat the Zacks Consensus Estimate by 46.7%. The bottom line increased 3.7% from the prior-year quarter's levels. The quarter's adjustments primarily eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities, among others. The company's GAAP loss was$ 76.26 per share ...